China Lashes Out at G-7, Von der Leyen for Criticism of Policies
China has attacked the Group of Seven nations for what it called interference in its internal affairs and chastised a top European official for criticizing Beijing's rare earth and economic policies.
Ministry of Foreign Affairs spokesman Guo Jiakun formally protested a statement issued by Canadian Prime Minister Mark Carney after the G-7 meeting in Alberta that called on China to 'refrain from market distortions and harmful overcapacity.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
21 minutes ago
- Bloomberg
SAP and IBM Unit Ensnared in $800 Million Quebec IT Fiasco
Software company SAP SE and an IBM Corp. subsidiary are embroiled in a C$1.1 billion ($810 million) technology boondoggle that triggered both a public inquiry and an anti-corruption investigation in Quebec. The Canadian province's Treasury Board President Sonia LeBel also ordered Quebec's procurement watchdog to conduct an 'in-depth analysis' of how the government awards technology contracts, she announced Monday. The mandate came after the ongoing inquiry revealed cost overruns, potential conflicts of interest and unexplained contracts for a bungled IT upgrade.
Hamilton Spectator
25 minutes ago
- Hamilton Spectator
Ontario's AI ecosystem: fueling real economic growth with record number of jobs and private investments
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) — Today, the Vector Institute released its fourth annual Ontario AI Snapshot, produced in partnership with Deloitte Canada. The research indicates that the province's AI sector has grown significantly, cementing Ontario's position as a leading global AI hub. Buoyed by its remarkable concentration of AI talent, the sector is attracting major investments and creating well-paying AI jobs that directly support economic growth. The data specifically indicates that: 'Canada ranks first among G7 countries in AI talent growth due in large measure to Ontario's strong and growing concentration of AI experts. Vector's latest AI snapshot confirms this. The data also indicates that Ontario is becoming a powerful draw for AI companies and investment, providing a direct boost to our economy. To maintain this momentum, we need to ensure leadership in other key areas: we need to increase R&D investment and step up our rate of adoption. Today's reality is that no matter the size of your business – no matter the field you're in or the market you serve – there is a place and a use for AI. It is time to use our AI advantage to make competitive gains, close the productivity gap and attract and retain top talent,' said Glenda Crisp, President and CEO of the Vector Institute. 'It is acknowledged worldwide that Canada leads in AI talent growth. Materially improving our compute infrastructure, R&D investment, and most significantly, adoption of AI solutions to drive productivity, are critical to retaining top-tier talent and training future talent. Ontario, as an AI hub, is seeing growing VC investments and a surge in new companies. Now is the time to scale these companies and make them globally successful to continue our leadership in the global AI community,' said Anthony Viel, CEO of Deloitte Canada. Covering the period from April 1, 2024 to March 31, 2025, the latest Ontario AI Snapshot tracks 10 metrics, which include AI job creation, investment and commercialization. These metrics serve as benchmarks for measuring the collective progress of governments, businesses, and institutions in strengthening Ontario's AI ecosystem. Further data on the growth of the Ontario AI ecosystem is included in this year's version of the Snapshot. The research is based on a combination of business executive surveys (185 executive survey responses), and market insights from industrial and public databases. About Vector Institute The Vector Institute is an independent, not-for-profit corporation dedicated to advancing artificial intelligence, excelling in machine learning and deep learning. Our vision is to drive excellence and leadership in Canada's knowledge, creation, and use of AI to foster economic growth and improve the lives of Canadians. The Vector Institute is funded by the Government of Ontario, the Government of Canada through CIFAR Pan-Canadian AI Strategy, and industry sponsors across Canada. For further information or media enquiries, please contact: media@
Yahoo
33 minutes ago
- Yahoo
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Novo Nordisk has been actively pursuing licensing deals over the past six months. These have helped the company improve its pipeline in its most important area. There are other good reasons to consider investing in Novo Nordisk right now. 10 stocks we like better than Novo Nordisk › It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. However, the past year has been challenging for the drugmaker. One reason behind its poor performance over the trailing-12-month period is that it has encountered clinical setbacks. CagriSema, an investigational weight loss medicine, performed well in phase 3 studies, but not quite as well as management had promised. Elsewhere, Novo Nordisk's biggest rival in this area, Eli Lilly, has registered significant clinical wins that arguably put it ahead in this fast-growing market. Still, Novo Nordisk hasn't said its last word yet. The company has recently made significant moves to strengthen its anti-obesity pipeline. Should investors buy the stock following these developments? On June 11, Deep Apple Therapeutics, a privately held biotech company, announced a licensing deal with Novo Nordisk. The former will utilize its proprietary platform, which leverages a virtual library powered by artificial intelligence (AI) to identify promising compounds rapidly. Deep Apple will aim to optimize novel compounds for obesity and other related diseases, and will receive up to $812 million, including an up-front payment and milestones for clinical and regulatory achievements. While it's too early to celebrate this deal -- it's still brand-new and hasn't led to any significant wins yet -- it's worth pointing out that Novo Nordisk has penned several such agreements since the CagriSema setback. One of the more promising of these agreements was with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings. Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that mimics the action of three separate gut hormones: GLP-1, GIP, and glucagon. Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple agonist. So, with this acquisition, Novo Nordisk is trying to catch up to its longtime competitor. This move, along with others, has helped expand Novo Nordisk's weight-management pipeline. Could that help the stock bounce back? In my view, Novo Nordisk's stock is attractive regardless of its recent shopping spree. Here's one reason. Its forward price-to-earnings (P/E) ratio is 19.6 at this writing, while the average for the healthcare industry is 16.2. Though that means Novo Nordisk is trading at a premium compared to its peers, its financial results justify that difference. In the first quarter, the company's net sales jumped 19% year over year to 78.1 billion Danish kroner ($12.1 billion), while its earnings per share rose by 15% to 6.53 DKK ($1). Revenue and earnings growth in that range is above what's considered "good" for a pharmaceutical company, especially one of this size. Perhaps Novo Nordisk was due for a sell-off -- its forward P/E looked extremely high a year ago. However, at current levels, shares now appear far more attractive, given the company's strong financial results. And when we take into account its pipeline and the recent deals it's made, Novo Nordisk looks even more promising -- the weight-management market is on an incredible growth path. Other than Eli Lilly, no company should seriously challenge Novo Nordisk anytime soon. In addition to its licensing deals, the Denmark-based drugmaker has promising, internally developed candidates. Novo Nordisk has just announced that it will start phase 3 studies for amycretin, an investigational weight loss product with both oral and subcutaneous formulations; this product delivered encouraging results in early-stage studies. Meanwhile, the company asked the U.S. Food and Drug Administration to approve an oral formulation of semaglutide (the active ingredient in Wegovy). In addition to its core area of expertise, Novo Nordisk has made a point of developing medicines in other fields, and has several promising candidates across various diseases. For all these reasons the stock looks like a buy at current levels, despite the challenges the company has faced in the past year. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? was originally published by The Motley Fool
